

David Knopman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5527354/publications.pdf>

Version: 2024-02-01

634
papers

82,252
citations

967

118
h-index

636

264
g-index

649
all docs

649
docs citations

649
times ranked

56043
citing authors

#	ARTICLE	IF	CITATIONS
1	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 263-269.	0.4	12,681
2	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. <i>Neuron</i> , 2011, 72, 245-256.	3.8	4,176
3	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. <i>Brain</i> , 2011, 134, 2456-2477.	3.7	3,913
4	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. <i>Lancet Neurology</i> , 2010, 9, 119-128.	4.9	3,792
5	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. <i>Lancet Neurology</i> , 2013, 12, 207-216.	4.9	3,378
6	Introduction to the recommendations from the National Institute on Aging and Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 257-262.	0.4	1,547
7	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016, 87, 539-547.	1.5	1,216
8	Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2009, 66, 1447-55.	4.9	1,160
9	Primary age-related tauopathy (PART): a common pathology associated with human aging. <i>Acta Neuropathologica</i> , 2014, 128, 755-766.	3.9	1,060
10	Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. <i>Brain</i> , 2009, 132, 1355-1365.	3.7	975
11	¹¹ C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. <i>Brain</i> , 2008, 131, 665-680.	3.7	819
12	Cardiovascular risk factors and cognitive decline in middle-aged adults. <i>Neurology</i> , 2001, 56, 42-48.	1.5	793
13	Alzheimer disease. <i>Nature Reviews Disease Primers</i> , 2021, 7, 33.	18.1	784
14	A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease. <i>New England Journal of Medicine</i> , 1992, 327, 1253-1259.	13.9	627
15	Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. <i>Brain</i> , 2006, 129, 1385-1398.	3.7	624
16	The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics. <i>Neuroepidemiology</i> , 2008, 30, 58-69.	1.1	623
17	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 205-216.	0.4	581
18	Neuropathologic Features of Amnesic Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2006, 63, 665.	4.9	562

#	ARTICLE	IF	CITATIONS
19	Association of Mediterranean Diet with Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 271-282.	1.2	540
20	An operational approach to National Institute on Aging's Alzheimer's Association criteria for preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2012, 71, 765-775.	2.8	520
21	Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs. <i>Alzheimer Disease and Associated Disorders</i> , 1997, 11, 13-21.	0.6	518
22	Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. <i>Nature Communications</i> , 2018, 9, 2098.	5.8	484
23	Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. <i>Hypertension</i> , 2016, 68, e67-e94.	1.3	482
24	Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 710-717.	0.4	461
25	Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1443.	3.8	451
26	Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. <i>JAMA Neurology</i> , 2017, 74, 1246.	4.5	404
27	Cascading network failure across the Alzheimer's disease spectrum. <i>Brain</i> , 2016, 139, 547-562.	3.7	401
28	Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. <i>Alzheimer's and Dementia</i> , 2011, 7, 80-93.	0.4	399
29	Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies. <i>NeuroImage</i> , 2008, 39, 1186-1197.	2.1	391
30	An autoradiographic evaluation of AV-1451 Tau PET in dementia. <i>Acta Neuropathologica Communications</i> , 2016, 4, 58.	2.4	388
31	Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau and amyloid positron emission tomography. <i>Alzheimer's and Dementia</i> , 2018, 14, 989-997.	0.4	386
32	DLB fluctuations. <i>Neurology</i> , 2004, 62, 181-187.	1.5	383
33	Non-Stationarity in the "Resting Brain" Modular Architecture. <i>PLoS ONE</i> , 2012, 7, e39731.	1.1	382
34	Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia. <i>Archives of Neurology</i> , 2006, 63, 674.	4.9	377
35	Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. <i>Neurology</i> , 2014, 82, 317-325.	1.5	361
36	Midlife Hypertension and 20-Year Cognitive Change. <i>JAMA Neurology</i> , 2014, 71, 1218.	4.5	358

#	ARTICLE	IF	CITATIONS
37	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. <i>Brain</i> , 2012, 135, 794-806.	3.7	355
38	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. <i>Lancet Neurology</i> , The, 2012, 11, 868-877.	4.9	355
39	Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. <i>Brain</i> , 2008, 131, 2957-2968.	3.7	354
40	Long-term tacrine (Cognex) treatment. <i>Neurology</i> , 1996, 47, 166-177.	1.5	340
41	TDP-43 is a key player in the clinical features associated with Alzheimer's disease. <i>Acta Neuropathologica</i> , 2014, 127, 811-824.	3.9	336
42	Brain β -amyloid load approaches a plateau. <i>Neurology</i> , 2013, 80, 890-896.	1.5	335
43	Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. <i>Alzheimer's and Dementia</i> , 2021, 17, 696-701.	0.4	330
44	TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2013, 8, 19.	4.4	323
45	Age, Sex, and APOE ϵ 4 Effects on Memory, Brain Structure, and β -Amyloid Across the Adult Life Span. <i>JAMA Neurology</i> , 2015, 72, 511.	4.5	305
46	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	4.9	302
47	Age-specific population frequencies of cerebral β -amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2014, 13, 997-1005.	4.9	297
48	Association Between Olfactory Dysfunction and Amnesic Mild Cognitive Impairment and Alzheimer Disease Dementia. <i>JAMA Neurology</i> , 2016, 73, 93.	4.5	294
49	MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. <i>Neurology</i> , 2003, 60, 253-260.	1.5	279
50	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. <i>Brain</i> , 2009, 132, 2932-2946.	3.7	277
51	Clinicopathologic and ¹¹ C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. <i>Brain</i> , 2015, 138, 1370-1381.	3.7	270
52	Validation of the Telephone Interview for Cognitive Status-modified in Subjects with Normal Cognition, Mild Cognitive Impairment, or Dementia. <i>Neuroepidemiology</i> , 2010, 34, 34-42.	1.1	245
53	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 676-685.	4.9	245
54	Age-specific and sex-specific prevalence of cerebral β -amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2017, 16, 435-444.	4.9	241

#	ARTICLE	IF	CITATIONS
55	Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 351-358.	0.6	241
56	Correlates of Cognitive Function in Middle-Aged Adults. <i>Gerontology</i> , 1998, 44, 95-105.	1.4	237
57	Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. <i>Neurology</i> , 2011, 77, 875-882.	1.5	233
58	Suspected non-Alzheimer disease pathophysiology " concept and controversy. <i>Nature Reviews Neurology</i> , 2016, 12, 117-124.	4.9	230
59	Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1452-1459.	1.4	227
60	Association of Midlife to Late-Life Blood Pressure Patterns With Incident Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 535.	3.8	227
61	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2316.	3.8	223
62	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. <i>Brain</i> , 2015, 138, 761-771.	3.7	222
63	Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia (bvFTD): Current Limitations and Future Directions. <i>Alzheimer Disease and Associated Disorders</i> , 2007, 21, S14-S18.	0.6	219
64	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. <i>Brain</i> , 2018, 141, 271-287.	3.7	218
65	Mild cognitive impairment due to Alzheimer disease in the community. <i>Annals of Neurology</i> , 2013, 74, 199-208.	2.8	215
66	Novel genetic loci underlying human intracranial volume identified through genome-wide association. <i>Nature Neuroscience</i> , 2016, 19, 1569-1582.	7.1	213
67	Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. <i>The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders</i> , 1997, 11 Suppl 2, S13-21.	0.6	213
68	Blood Pressure and White-Matter Disease Progression in a Biethnic Cohort. <i>Stroke</i> , 2010, 41, 3-8.	1.0	209
69	Mild cognitive impairment and dementia prevalence: The Atherosclerosis Risk in Communities Neurocognitive Study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 1-11.	1.2	209
70	Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2013, 12, 149-156.	4.9	204
71	Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI Study. <i>Alzheimer's and Dementia</i> , 2009, 5, 207-214.	0.4	199
72	Mild cognitive impairment associated with limbic and neocortical lewy body disease: a clinicopathological study. <i>Brain</i> , 2010, 133, 540-556.	3.7	195

#	ARTICLE	IF	CITATIONS
73	Vascular Dementia in a Population-Based Autopsy Study. <i>Archives of Neurology</i> , 2003, 60, 569.	4.9	194
74	TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. <i>Nature</i> , 2022, 603, 124-130.	13.7	193
75	Essentials of the Proper Diagnoses of Mild Cognitive Impairment, Dementia, and Major Subtypes of Dementia. <i>Mayo Clinic Proceedings</i> , 2003, 78, 1290-1308.	1.4	187
76	Comparison of ¹⁸ F-FDG and PiB PET in Cognitive Impairment. <i>Journal of Nuclear Medicine</i> , 2009, 50, 878-886.	2.8	183
77	Estimating the Number of Persons with Frontotemporal Lobar Degeneration in the US Population. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 330-335.	1.1	183
78	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. <i>Neurology</i> , 2013, 81, 1732-1740.	1.5	182
79	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	4.5	182
80	Antemortem diagnosis of frontotemporal lobar degeneration. <i>Annals of Neurology</i> , 2005, 57, 480-488.	2.8	181
81	Association of type 2 diabetes with brain atrophy and cognitive impairment. <i>Neurology</i> , 2014, 82, 1132-1141.	1.5	180
82	Subjective cognitive decline and risk of MCI. <i>Neurology</i> , 2018, 91, e300-e312.	1.5	176
83	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	4.9	175
84	Cardiac Disease Associated With Increased Risk of Nonamnesic Cognitive Impairment. <i>JAMA Neurology</i> , 2013, 70, 374.	4.5	173
85	Association of Duration and Severity of Diabetes Mellitus With Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2008, 65, 1066-73.	4.9	171
86	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. <i>Brain</i> , 2015, 138, 3747-3759.	3.7	170
87	Prominent phenotypic variability associated with mutations in Progranulin. <i>Neurobiology of Aging</i> , 2009, 30, 739-751.	1.5	166
88	Longitudinal Study of Death and Institutionalization in Patients with Primary Degenerative Dementia. <i>Journal of the American Geriatrics Society</i> , 1988, 36, 108-112.	1.3	165
89	Multimodality imaging characteristics of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2012, 33, 2091-2105.	1.5	162
90	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. <i>Cortex</i> , 2017, 97, 143-159.	1.1	162

#	ARTICLE	IF	CITATIONS
91	Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. <i>Annals of Neurology</i> , 2010, 67, 308-316.	2.8	160
92	Association of Lifetime Intellectual Enrichment With Cognitive Decline in the Older Population. <i>JAMA Neurology</i> , 2014, 71, 1017.	4.5	160
93	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. <i>JAMA Neurology</i> , 2016, 73, 85.	4.5	160
94	Plasma and CSF neurofilament light. <i>Neurology</i> , 2019, 93, e252-e260.	1.5	160
95	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. <i>Lancet Neurology</i> , The, 2017, 16, 917-924.	4.9	159
96	Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2003, 60, 1777.	4.9	158
97	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 172-179.	1.5	158
98	Brain injury biomarkers are not dependent on β -amyloid in normal elderly. <i>Annals of Neurology</i> , 2013, 73, 472-480.	2.8	155
99	Antemortem MRI based STructural Abnormality INdex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. <i>NeuroImage</i> , 2008, 42, 559-567.	2.1	152
100	18 F-AV45 tau and 125 I-amyloid positron emission tomography imaging in dementia with Lewy bodies. <i>Annals of Neurology</i> , 2017, 81, 58-67.	2.8	152
101	Association of Excessive Daytime Sleepiness With Longitudinal β -Amyloid Accumulation in Elderly Persons Without Dementia. <i>JAMA Neurology</i> , 2018, 75, 672.	4.5	150
102	Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. <i>JAMA Neurology</i> , 2017, 74, 1073.	4.5	149
103	Utility of the Functional Activities Questionnaire for Distinguishing Mild Cognitive Impairment From Very Mild Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 348-353.	0.6	148
104	Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem 1 H MR Spectroscopy Metabolite Measurements. <i>Radiology</i> , 2008, 248, 210-220.	3.6	147
105	Rates of cerebral atrophy differ in different degenerative pathologies. <i>Brain</i> , 2006, 130, 1148-1158.	3.7	146
106	Dementia with Lewy bodies. <i>Neurology</i> , 2014, 83, 801-809.	1.5	143
107	Association of diabetes with amnesic and nonamnesic mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2014, 10, 18-26.	0.4	141
108	Patterns of Care in the Early Stages of Alzheimer's Disease: Impediments to Timely Diagnosis. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 300-304.	1.3	139

#	ARTICLE	IF	CITATIONS
109	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2015, 129, 757-762.	3.9	139
110	A phase 3 trial of IV immunoglobulin for Alzheimer disease. <i>Neurology</i> , 2017, 88, 1768-1775.	1.5	136
111	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. <i>Annals of Neurology</i> , 2017, 82, 706-718.	2.8	136
112	Multimorbidity and Risk of Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1783-1790.	1.3	135
113	Diabetes and Elevated Hemoglobin A1c Levels Are Associated with Brain Hypometabolism but Not Amyloid Accumulation. <i>Journal of Nuclear Medicine</i> , 2014, 55, 759-764.	2.8	134
114	Relative Intake of Macronutrients Impacts Risk of Mild Cognitive Impairment or Dementia. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 329-339.	1.2	133
115	The bivariate distribution of amyloid- β and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	3.7	129
116	Retinal microvascular abnormalities and subclinical magnetic resonance imaging brain infarct: a prospective study. <i>Brain</i> , 2010, 133, 1987-1993.	3.7	127
117	White matter hyperintensities: relationship to amyloid and tau burden. <i>Brain</i> , 2019, 142, 2483-2491.	3.7	126
118	Vascular Imaging Abnormalities and Cognition. <i>Stroke</i> , 2015, 46, 433-440.	1.0	125
119	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). <i>Acta Neuropathologica</i> , 2017, 133, 705-715.	3.9	125
120	Practice Effects and Longitudinal Cognitive Change in Normal Aging vs. Incident Mild Cognitive Impairment and Dementia in The Mayo Clinic Study of Aging. <i>Clinical Neuropsychologist</i> , 2013, 27, 1247-1264.	1.5	124
121	Computed tomographic scan correlates of auditory comprehension deficits in aphasia: A prospective recovery study. <i>Annals of Neurology</i> , 1983, 13, 558-566.	2.8	123
122	Sleep characteristics and risk of dementia and Alzheimer's disease: The Atherosclerosis Risk in Communities Study. <i>Alzheimer's and Dementia</i> , 2018, 14, 157-166.	0.4	122
123	<i>APOE</i> ϵ 4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. <i>Neurology</i> , 2018, 91, e1182-e1195.	1.5	122
124	Rates of β -amyloid accumulation are independent of hippocampal neurodegeneration. <i>Neurology</i> , 2014, 82, 1605-1612.	1.5	119
125	The ARIC-PET amyloid imaging study. <i>Neurology</i> , 2016, 87, 473-480.	1.5	119
126	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. <i>Journal of Neuroscience</i> , 2014, 34, 16247-16255.	1.7	117

#	ARTICLE	IF	CITATIONS
127	Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. <i>Journal of Clinical Investigation</i> , 2020, 130, 6080-6092.	3.9	117
128	Spt4 selectively regulates the expression of <i>C9orf72</i> sense and antisense mutant transcripts. <i>Science</i> , 2016, 353, 708-712.	6.0	116
129	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. <i>JAMA Neurology</i> , 2018, 75, 970.	4.5	116
130	Systemic inflammation during midlife and cognitive change over 20 years: The ARIC Study. <i>Neurology</i> , 2019, 92, e1256-e1267.	1.5	116
131	Arterial stiffness and dementia pathology. <i>Neurology</i> , 2018, 90, e1248-e1256.	1.5	114
132	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021, 78, 1108.	4.5	114
133	Performance of plasma phosphorylated tau 181 and 217 in the community. <i>Nature Medicine</i> , 2022, 28, 1398-1405.	15.2	114
134	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2015, 36, 452-461.	1.5	113
135	Tau positron emission tomography correlates with neuropathology findings. <i>Alzheimer's and Dementia</i> , 2020, 16, 561-571.	0.4	113
136	Association of C-reactive protein with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2009, 5, 398-405.	0.4	111
137	Coronary heart disease is associated with non-amnesic mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010, 31, 1894-1902.	1.5	111
138	Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. <i>Alzheimer's and Dementia</i> , 2017, 13, 168-177.	0.4	110
139	Alzheimer's Disease-Related Dementias Summit 2016: National research priorities. <i>Neurology</i> , 2017, 89, 2381-2391.	1.5	109
140	¹⁸ F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. <i>Neurobiology of Aging</i> , 2014, 35, 2096-2106.	1.5	108
141	Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. <i>Neurology</i> , 2005, 65, 876-881.	1.5	107
142	Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, 1226-1234.	0.4	107
143	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. <i>JAMA Neurology</i> , 2017, 74, 718.	4.5	107
144	Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. <i>Movement Disorders</i> , 2009, 24, 1375-1379.	2.2	105

#	ARTICLE	IF	CITATIONS
145	Vascular Risk Factors: Imaging and Neuropathologic Correlates. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 699-709.	1.2	104
146	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. <i>Acta Neuropathologica</i> , 2015, 130, 863-876.	3.9	104
147	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 56-64.	4.9	104
148	The Association of Late-Life Diabetes Status and Hyperglycemia With Incident Mild Cognitive Impairment and Dementia: The ARIC Study. <i>Diabetes Care</i> , 2019, 42, 1248-1254.	4.3	104
149	Revisiting FDA Approval of Aducanumab. <i>New England Journal of Medicine</i> , 2021, 385, 769-771.	13.9	104
150	Recommendations of the Alzheimer's Disease-Related Dementias Conference. <i>Neurology</i> , 2014, 83, 851-860.	1.5	103
151	Impact of Differential Attrition on the Association of Education With Cognitive Change Over 20 Years of Follow-up: The ARIC Neurocognitive Study. <i>American Journal of Epidemiology</i> , 2014, 179, 956-966.	1.6	102
152	Neuropsychiatric symptoms, <i>APOE</i> $\epsilon 4$, and the risk of incident dementia. <i>Neurology</i> , 2015, 84, 935-943.	1.5	101
153	Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging. <i>Neurology</i> , 2015, 84, 1433-1442.	1.5	101
154	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. <i>Alzheimer's and Dementia</i> , 2018, 14, 563-575.	0.4	98
155	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 1144-1153.	2.2	98
156	Midlife systemic inflammatory markers are associated with late-life brain volume. <i>Neurology</i> , 2017, 89, 2262-2270.	1.5	97
157	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	4.9	97
158	MRI and MRS predictors of mild cognitive impairment in a population-based sample. <i>Neurology</i> , 2013, 81, 126-133.	1.5	95
159	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 83-91.	1.8	94
160	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 862-871.	0.4	93
161	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. <i>Neurology</i> , 2012, 79, 553-560.	1.5	91
162	Genome-wide analyses as part of the international FTLTDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLTDP. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	3.9	90

#	ARTICLE	IF	CITATIONS
163	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. <i>Acta Neuropathologica</i> , 2015, 130, 559-573.	3.9	89
164	Decline in Weight and Incident Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2016, 73, 439.	4.5	89
165	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. <i>Alzheimer's and Dementia</i> , 2022, 18, 1128-1140.	0.4	88
166	Measuring cognition and function in the preclinical stage of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 64-75.	1.8	87
167	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	3.9	87
168	Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 21-30.	1.2	86
169	Survival Study of Vascular Dementia in Rochester, Minnesota. <i>Archives of Neurology</i> , 2003, 60, 85.	4.9	85
170	Performance of the CogState computerized battery in the Mayo Clinic Study on Aging. <i>Alzheimer's and Dementia</i> , 2015, 11, 1367-1376.	0.4	85
171	Association of midlife lipids with 20-year cognitive change: A cohort study. <i>Alzheimer's and Dementia</i> , 2018, 14, 167-177.	0.4	84
172	Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease. <i>Stroke</i> , 2017, 48, 3196-3202.	1.0	83
173	Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. <i>Neurobiology of Aging</i> , 2015, 36, 1765.e7-1765.e16.	1.5	82
174	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. <i>JAMA Neurology</i> , 2017, 74, 801.	4.5	81
175	Diabetes, Prediabetes, and Brain Volumes and Subclinical Cerebrovascular Disease on MRI: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). <i>Diabetes Care</i> , 2017, 40, 1514-1521.	4.3	81
176	Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. <i>Brain Communications</i> , 2020, 2, fcaa068.	1.5	81
177	Utility of the global CDR [®] plus NACC FTD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. <i>Alzheimer's and Dementia</i> , 2020, 16, 106-117.	0.4	81
178	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1005-1014.	0.4	80
179	Comparison of Gait Parameters for Predicting Cognitive Decline: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 559-567.	1.2	79
180	Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. <i>Sleep Medicine</i> , 2017, 32, 236-243.	0.8	79

#	ARTICLE	IF	CITATIONS
181	Metabolic Syndrome, Inflammation, and Nonamnesic Mild Cognitive Impairment in Older Persons. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 11-18.	0.6	78
182	Incidence and Causes of Nondegenerative Nonvascular Dementia. <i>Archives of Neurology</i> , 2006, 63, 218.	4.9	77
183	Impaired Lung Function, Lung Disease, and Risk of Incident Dementia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1385-1396.	2.5	77
184	Anesthesia and Incident Dementia: A Population-Based, Nested, Case-Control Study. <i>Mayo Clinic Proceedings</i> , 2013, 88, 552-561.	1.4	76
185	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. <i>Acta Neuropathologica</i> , 2017, 134, 255-269.	3.9	76
186	Hippocampal Volumes, Proton Magnetic Resonance Spectroscopy Metabolites, and Cerebrovascular Disease in Mild Cognitive Impairment Subtypes. <i>Archives of Neurology</i> , 2008, 65, 1621-8.	4.9	75
187	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. <i>Neurobiology of Aging</i> , 2014, 35, 2421.e13-2421.e17.	1.5	74
188	Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: The Atherosclerosis Risk in Communities Study. <i>Alzheimer's and Dementia</i> , 2018, 14, 1406-1415.	0.4	74
189	Predicting future rates of tau accumulation on PET. <i>Brain</i> , 2020, 143, 3136-3150.	3.7	74
190	Association of hypometabolism and amyloid levels in aging, normal subjects. <i>Neurology</i> , 2014, 82, 1959-1967.	1.5	73
191	[¹⁸ F]AV-1451 tau-PET and primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 83, 599-611.	2.8	73
192	Language and behavior domains enhance the value of the clinical dementia rating scale. <i>Alzheimer's and Dementia</i> , 2011, 7, 293-299.	0.4	72
193	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. <i>Brain</i> , 2019, 142, 1134-1147.	3.7	72
194	Effect of intellectual enrichment on AD biomarker trajectories. <i>Neurology</i> , 2016, 86, 1128-1135.	1.5	71
195	Association Between Mentally Stimulating Activities in Late Life and the Outcome of Incident Mild Cognitive Impairment, With an Analysis of the APOE ϵ 4 Genotype. <i>JAMA Neurology</i> , 2017, 74, 332.	4.5	71
196	Argyrophilic grains: A distinct disease or an additive pathology?. <i>Neurobiology of Aging</i> , 2008, 29, 566-573.	1.5	70
197	Progranulin protein levels are differently regulated in plasma and CSF. <i>Neurology</i> , 2014, 82, 1871-1878.	1.5	70
198	Smoking and white matter hyperintensity progression. <i>Neurology</i> , 2015, 84, 841-848.	1.5	70

#	ARTICLE	IF	CITATIONS
199	Long-term Retention of Implicitly Acquired Learning in Patients with Alzheimer's Disease. <i>Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology</i> , 1991, 13, 880-894.	1.4	69
200	Retinal Microvascular Signs and 10-Year Risk of Cerebral Atrophy. <i>Stroke</i> , 2010, 41, 1826-1828.	1.0	69
201	TYROBP genetic variants in early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 48, 222.e9-222.e15.	1.5	69
202	Unaware learning versus preserved learning in pharmacologic amnesia: similarities and differences. <i>Journal of Experimental Psychology: Learning Memory and Cognition</i> , 1991, 17, 1017-29.	0.7	69
203	Association of Prior Stroke With Cognitive Function and Cognitive Impairment. <i>Archives of Neurology</i> , 2009, 66, 614-9.	4.9	68
204	Amyloid- β^2 deposition and regional grey matter atrophy rates in dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 2740-2750.	3.7	68
205	Entorhinal cortex tau, amyloid- β^2 , cortical thickness and memory performance in non-demented subjects. <i>Brain</i> , 2019, 142, 1148-1160.	3.7	68
206	Artificial Intelligence-Driven Electrocardiography to Predict Incident Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e009355.	2.1	68
207	Dementia and Cerebrovascular Disease. <i>Mayo Clinic Proceedings</i> , 2006, 81, 223-230.	1.4	67
208	Associations of microalbuminuria with brain atrophy and white matter hyperintensities in hypertensive sibships. <i>Journal of the Neurological Sciences</i> , 2008, 271, 53-60.	0.3	67
209	Spectrum of cognition short of dementia. <i>Neurology</i> , 2015, 85, 1712-1721.	1.5	67
210	Obesity, Insulin Resistance, and Incident Small Vessel Disease on Magnetic Resonance Imaging. <i>Stroke</i> , 2015, 46, 3131-3136.	1.0	67
211	Genome-wide Studies of Verbal Declarative Memory in Nondemented Older People: The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. <i>Biological Psychiatry</i> , 2015, 77, 749-763.	0.7	67
212	[¹⁸ F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 83, 248-257.	2.8	67
213	FDG-PET in tau-negative amnesic dementia resembles that of autopsy-proven hippocampal sclerosis. <i>Brain</i> , 2018, 141, 1201-1217.	3.7	67
214	Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. <i>Acta Neuropathologica</i> , 2022, 144, 27-44.	3.9	67
215	Incidence of Vascular Dementia in Rochester, Minn, 1985-1989. <i>Archives of Neurology</i> , 2002, 59, 1605.	4.9	66
216	Developmental Aspects of the Intracerebral Microvasculature and Perivascular Spaces: Insights into Brain Response to Late-Life Diseases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 1060-1069.	0.9	66

#	ARTICLE	IF	CITATIONS
217	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. <i>JAMA Neurology</i> , 2019, 76, 187.	4.5	66
218	Withdrawal of Neuroleptic Medications from Institutionalized Dementia Patients: Results of a Double-Blind, Baseline-Treatmentâ€”Controlled Pilot Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1997, 10, 119-126.	1.2	65
219	Selective Worsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly Persons With β -Amyloidosis. <i>JAMA Neurology</i> , 2013, 70, 1030.	4.5	65
220	Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 573-581.	1.2	65
221	Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. <i>Brain</i> , 2019, 142, 443-459.	3.7	65
222	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. <i>Acta Neuropathologica</i> , 2019, 137, 227-238.	3.9	65
223	β -Amyloid PET and neuropathology in dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e282-e291.	1.5	65
224	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
225	Intracranial atherosclerosis and dementia. <i>Neurology</i> , 2017, 88, 1556-1563.	1.5	64
226	Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. <i>Molecular Neurodegeneration</i> , 2014, 9, 38.	4.4	63
227	Neuroimaging Correlates of Cerebral Microbleeds. <i>Stroke</i> , 2017, 48, 2964-2972.	1.0	63
228	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. <i>NeuroImage</i> , 2021, 224, 117433.	2.1	63
229	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. <i>Neurology</i> , 2019, 93, e29-e39.	1.5	62
230	β -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. <i>Neurology</i> , 2020, 95, e3257-e3268.	1.5	62
231	Characteristics of the dementia in late-onset metachromatic leukodystrophy. <i>Neurology</i> , 1994, 44, 662-662.	1.5	62
232	Risk and protective factors for cognitive impairment in persons aged 85 years and older. <i>Neurology</i> , 2015, 84, 1854-1861.	1.5	61
233	Comparison of Imaging Biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. <i>Archives of Neurology</i> , 2012, 69, 614.	4.9	60
234	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. <i>Neurology</i> , 2018, 90, e947-e954.	1.5	60

#	ARTICLE	IF	CITATIONS
235	Midlife cardiovascular health and 20-year cognitive decline: Atherosclerosis Risk in Communities Study results. <i>Alzheimer's and Dementia</i> , 2018, 14, 579-589.	0.4	60
236	Association of Apolipoprotein E ϵ 4 With Transactive Response DNA-Binding Protein 43. <i>JAMA Neurology</i> , 2018, 75, 1347.	4.5	60
237	Cognitive outcomes of patients undergoing therapeutic hypothermia after cardiac arrest. <i>Neurology</i> , 2013, 81, 40-45.	1.5	59
238	Life-course blood pressure in relation to brain volumes. <i>Alzheimer's and Dementia</i> , 2016, 12, 890-899.	0.4	59
239	The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study. <i>Neurobiology of Aging</i> , 2018, 68, 26-33.	1.5	59
240	Atrial fibrillation, cognitive impairment, and neuroimaging. <i>Alzheimer's and Dementia</i> , 2016, 12, 391-398.	0.4	58
241	The critical role Wernicke's area in sentence repetition. <i>Annals of Neurology</i> , 1985, 17, 549-557.	2.8	57
242	Off-Label Medication Use in Frontotemporal Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 128-133.	0.9	57
243	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. <i>JAMA Neurology</i> , 2014, 71, 1547.	4.5	57
244	Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NC). <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 73-82.	1.2	57
245	Alzheimer Disease. <i>Mayo Clinic Proceedings</i> , 2017, 92, 978-994.	1.4	57
246	Lowering of Amyloid-Beta by β -Secretase Inhibitors " Some Informative Failures. <i>New England Journal of Medicine</i> , 2019, 380, 1476-1478.	13.9	56
247	The neuropsychology of normal aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 84-92.	0.4	55
248	Normative Data for 8 Neuropsychological Tests in Older Blacks and Whites From the Atherosclerosis Risk in Communities (ARIC) Study. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 32-44.	0.6	55
249	Association of Mild Cognitive Impairment With Exposure to General Anesthesia for Surgical and Nonsurgical Procedures. <i>Mayo Clinic Proceedings</i> , 2016, 91, 208-217.	1.4	55
250	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. <i>Neurology</i> , 2018, 90, e466-e473.	1.5	55
251	Midlife and Late-Life Vascular Risk Factors and White Matter Microstructural Integrity: The Atherosclerosis Risk in Communities Neurocognitive Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	54
252	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 23, 101823.	1.4	54

#	ARTICLE	IF	CITATIONS
253	Cortical β -amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. <i>Translational Psychiatry</i> , 2019, 9, 123.	2.4	54
254	Association of Central Arterial Stiffness and Pressure Pulsatility with Mild Cognitive Impairment and Dementia: The Atherosclerosis Risk in Communities Study-Neurocognitive Study (ARIC-NCS). <i>Journal of Alzheimer's Disease</i> , 2017, 57, 195-204.	1.2	53
255	Cerebral microbleeds. <i>Neurology</i> , 2019, 92, e253-e262.	1.5	53
256	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. <i>International Psychogeriatrics</i> , 2018, 30, 245-251.	0.6	52
257	A brief history of "Alzheimer disease". <i>Neurology</i> , 2019, 92, 1053-1059.	1.5	52
258	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.5	52
259	Deep learning-based brain age prediction in normal aging and dementia. <i>Nature Aging</i> , 2022, 2, 412-424.	5.3	52
260	Heart Disease and Dementia: A Population-based Study. <i>American Journal of Epidemiology</i> , 2006, 163, 135-141.	1.6	51
261	Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals. <i>Annals of Neurology</i> , 2017, 81, 871-882.	2.8	51
262	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. <i>Neurobiology of Aging</i> , 2019, 77, 26-36.	1.5	51
263	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. <i>Brain</i> , 2020, 143, 2281-2294.	3.7	51
264	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. <i>Annals of Neurology</i> , 2018, 84, 705-716.	2.8	49
265	Computerized Analysis of Speech and Language to Identify Psycholinguistic Correlates of Frontotemporal Lobar Degeneration. <i>Cognitive and Behavioral Neurology</i> , 2010, 23, 165-177.	0.5	48
266	The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal) <i>Overlock</i> 10 Tf 50 22	0.4	48
267	Hypothyroidism and Risk of Mild Cognitive Impairment in Elderly Persons. <i>JAMA Neurology</i> , 2014, 71, 201.	4.5	48
268	Duration and Pathologic Correlates of Lewy Body Disease. <i>JAMA Neurology</i> , 2017, 74, 310.	4.5	48
269	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 927-939.	0.4	48
270	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 181-195.	1.2	48

#	ARTICLE	IF	CITATIONS
271	Use of the CDR [®] plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium. <i>Alzheimer's and Dementia</i> , 2020, 16, 79-90.	0.4	48
272	MRI Correlates of Protein Deposition and Disease Severity in Postmortem Frontotemporal Lobar Degeneration. <i>Neurodegenerative Diseases</i> , 2009, 6, 106-117.	0.8	47
273	Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. <i>Clinical Neuropsychologist</i> , 2017, 31, 99-117.	1.5	47
274	Subtypes of dementia with Lewy bodies are associated with α -synuclein and tau distribution. <i>Neurology</i> , 2020, 95, e155-e165.	1.5	47
275	Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. <i>Neurology</i> , 2013, 80, 2130-2137.	1.5	46
276	Correlates of Dementia and Mild Cognitive Impairment in Patients With Atrial Fibrillation: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC [®] NCS). <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	46
277	Association of Ischemic Stroke Incidence, Severity, and Recurrence With Dementia in the Atherosclerosis Risk in Communities Cohort Study. <i>JAMA Neurology</i> , 2022, 79, 271.	4.5	46
278	Invited Commentary: Albuminuria and Microvascular Disease of the Brain--A Shared Pathophysiology. <i>American Journal of Epidemiology</i> , 2010, 171, 287-289.	1.6	45
279	Predicting functional decline in behavioural variant frontotemporal dementia. <i>Brain</i> , 2011, 134, 432-448.	3.7	45
280	Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer [®] 's disease using the Multiple Sleep Latency Test. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 76.	3.0	45
281	Antemortem MRI findings associated with microinfarcts at autopsy. <i>Neurology</i> , 2014, 82, 1951-1958.	1.5	45
282	Influence of amyloid and <i>APOE</i> on cognitive performance in a late middle-aged cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, 281-291.	0.4	45
283	Association of Brain Magnetic Resonance Imaging Signs With Cognitive Outcomes in Persons With Nonimpaired Cognition and Mild Cognitive Impairment. <i>JAMA Network Open</i> , 2019, 2, e193359.	2.8	45
284	Dementia in late-onset epilepsy. <i>Neurology</i> , 2020, 95, e3248-e3256.	1.5	45
285	Protein contributions to brain atrophy acceleration in Alzheimer [®] 's disease and primary age-related tauopathy. <i>Brain</i> , 2020, 143, 3463-3476.	3.7	45
286	Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. <i>NeuroImage: Clinical</i> , 2013, 2, 249-257.	1.4	44
287	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. <i>Neurology</i> , 2016, 87, 2317-2323.	1.5	44
288	Leisure-time physical activity sustained since midlife and preservation of cognitive function: The Atherosclerosis Risk in Communities Study. <i>Alzheimer's and Dementia</i> , 2019, 15, 273-281.	0.4	44

#	ARTICLE	IF	CITATIONS
289	Patterns of Brain Atrophy in Clinical Variants of Frontotemporal Lobar Degeneration. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 35, 34-50.	0.7	42
290	The Brain in Kidney Disease (BRINK) Cohort Study: Design and Baseline Cognitive Function. <i>American Journal of Kidney Diseases</i> , 2016, 67, 593-600.	2.1	42
291	The Cross-sectional and Longitudinal Associations Between IL-6, IL-10, and TNF α and Cognitive Outcomes in the Mayo Clinic Study of Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1289-1295.	1.7	42
292	Mortality in Mild Cognitive Impairment Varies by Subtype, Sex, and Lifestyle Factors: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1237-1245.	1.2	41
293	The role of cerebrovascular disease when there is concomitant Alzheimer disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 952-956.	1.8	41
294	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 257-266.	0.4	41
295	Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 792-799.	1.3	41
296	Association of Apolipoprotein E ϵ 4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. <i>JAMA Network Open</i> , 2019, 2, e1913909.	2.8	41
297	Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2019, 15, 878-887.	0.4	41
298	Social support and cognition in a community-based cohort: the Atherosclerosis Risk in Communities (ARIC) study. <i>Age and Ageing</i> , 2016, 45, 475-480.	0.7	40
299	Prevalence and Natural History of Superficial Siderosis. <i>Stroke</i> , 2017, 48, 3210-3214.	1.0	40
300	Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1250-1263.	1.7	40
301	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. <i>Acta Neuropathologica Communications</i> , 2019, 7, 150.	2.4	40
302	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. <i>Annals of Neurology</i> , 2019, 86, 866-877.	2.8	40
303	Passive case-finding for Alzheimer's disease and dementia in two U.S. communities. <i>Alzheimer's and Dementia</i> , 2011, 7, 53-60.	0.4	39
304	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. <i>Stroke</i> , 2019, 50, 3037-3044.	1.0	39
305	Longitudinal structural and metabolic changes in frontotemporal dementia. <i>Neurology</i> , 2020, 95, e140-e154.	1.5	39
306	Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease. <i>NeuroImage</i> , 2015, 113, 61-69.	2.1	38

#	ARTICLE	IF	CITATIONS
307	Comparison of variables associated with cerebrospinal fluid neurofilament, total τ , and neurogranin. <i>Alzheimer's and Dementia</i> , 2019, 15, 1437-1447.	0.4	38
308	Quantity and quality of mental activities and the risk of incident mild cognitive impairment. <i>Neurology</i> , 2019, 93, e548-e558.	1.5	38
309	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 37-48.	0.4	38
310	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. <i>Brain Communications</i> , 2021, 3, fcab106.	1.5	38
311	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. <i>NeuroImage</i> , 2021, 231, 117845.	2.1	38
312	White Matter Reference Region in PET Studies of ^{11}C -Pittsburgh Compound B Uptake: Effects of Age and Amyloid- β^2 Deposition. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1583-1589.	2.8	37
313	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. <i>Brain</i> , 2019, 142, 3621-3635.	3.7	37
314	<i>APOE3</i> -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. <i>Science Translational Medicine</i> , 2021, 13, eabc9375.	5.8	37
315	Type 2 Diabetes and Cognitive Decline Over 14 Years in Middle-Aged African Americans and Whites: The ARIC Brain MRI Study. <i>Neuroepidemiology</i> , 2014, 43, 220-227.	1.1	36
316	Disrupted functional connectivity in primary progressive apraxia of speech. <i>NeuroImage: Clinical</i> , 2018, 18, 617-629.	1.4	36
317	Clinical Features of Pathologic Subtypes of Behavioral-Variant Frontotemporal Dementia. <i>Archives of Neurology</i> , 2007, 64, 1611.	4.9	35
318	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. <i>Neurobiology of Aging</i> , 2015, 36, 2010-2017.	1.5	35
319	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1609-1616.	1.2	35
320	Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation. <i>Alzheimer's and Dementia</i> , 2017, 13, 267-273.	0.4	35
321	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1516-1523.	1.4	35
322	Bad news and good news in AD, and how to reconcile them. <i>Nature Reviews Neurology</i> , 2019, 15, 61-62.	4.9	35
323	Clinical Trial Design Issues in Mild to Moderate Alzheimer Disease. <i>Cognitive and Behavioral Neurology</i> , 2008, 21, 197-201.	0.5	34
324	Differences in rate of functional decline across three dementia types. <i>Alzheimer's and Dementia</i> , 2013, 9, S63-71.	0.4	34

#	ARTICLE	IF	CITATIONS
325	Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. <i>Molecular Neurodegeneration</i> , 2016, 11, 31.	4.4	34
326	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 739-749.	1.4	34
327	Mediterranean Diet and Late-Life Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 686.	3.8	33
328	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 41-48.	1.1	33
329	[P2415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN. <i>Alzheimer's and Dementia</i> , 2017, 13, P792.	0.4	33
330	Leisure-Time Physical Activity and the Risk of Incident Dementia: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 149-155.	1.2	33
331	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. <i>Brain</i> , 2019, 142, 2466-2482.	3.7	33
332	MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 105-113.	2.2	33
333	Mayo Normative Studies: Regression-Based Normative Data for the Auditory Verbal Learning Test for Ages 30-91 Years and the Importance of Adjusting for Sex. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 211-226.	1.2	33
334	Albuminuria and Estimated GFR as Risk Factors for Dementia in Midlife and Older Age: Findings From the ARIC Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 775-783.	2.1	33
335	Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience. <i>Current Alzheimer Research</i> , 2015, 12, 607-613.	0.7	33
336	Dietary antioxidant intake and cognitive performance in middle-aged adults. <i>Public Health Nutrition</i> , 2000, 3, 337-343.	1.1	32
337	Current treatment of mild cognitive impairment and Alzheimer's disease. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 365-371.	2.0	32
338	Association of hospitalization with long-term cognitive and brain MRI changes in the ARIC cohort. <i>Neurology</i> , 2015, 84, 1443-1453.	1.5	32
339	<i>MAPT</i> haplotype H1G is associated with increased risk of dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2016, 12, 1297-1304.	0.4	32
340	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. <i>Movement Disorders</i> , 2016, 31, 989-994.	2.2	32
341	Association of white matter microstructural integrity with cognition and dementia. <i>Neurobiology of Aging</i> , 2019, 83, 63-72.	1.5	32
342	Predicting Progression to Mild Cognitive Impairment. <i>Annals of Neurology</i> , 2019, 85, 155-160.	2.8	32

#	ARTICLE	IF	CITATIONS
343	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€œEXAMINER as a potential clinical trial endpoint. <i>Alzheimer's and Dementia</i> , 2020, 16, 11-21.	0.4	32
344	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. <i>Alzheimer's and Dementia</i> , 2020, 16, 22-36.	0.4	32
345	A computational model of neurodegeneration in Alzheimerâ€™s disease. <i>Nature Communications</i> , 2022, 13, 1643.	5.8	32
346	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 199.	3.0	32
347	Characterizing cognitive performance in a large longitudinal study of aging with computerized semantic indices of verbal fluency. <i>Neuropsychologia</i> , 2016, 89, 42-56.	0.7	31
348	Genome-wide association study of 23,500 individuals identifies 7 loci associated with brain ventricular volume. <i>Nature Communications</i> , 2018, 9, 3945.	5.8	31
349	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. <i>NeuroImage: Clinical</i> , 2018, 19, 939-947.	1.4	31
350	Retinal signs and risk of incident dementia in the Atherosclerosis Risk in Communities study. <i>Alzheimer's and Dementia</i> , 2019, 15, 477-486.	0.4	31
351	Cerebral microbleed incidence, relationship to amyloid burden. <i>Neurology</i> , 2020, 94, e190-e199.	1.5	31
352	<scp>NIAâ€œAA</scp> Alzheimer's Disease Framework: Clinical Characterization of Stages. <i>Annals of Neurology</i> , 2021, 89, 1145-1156.	2.8	31
353	Age and apoE associations with complex pathologic features in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2008, 273, 34-39.	0.3	30
354	Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1069-1082.	1.2	30
355	LRRK2 variation and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 98-103.	1.1	30
356	The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2018, 66, 68-74.	1.5	30
357	Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 1244-1250.	1.7	30
358	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1195-1205.	1.4	30
359	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. <i>Brain</i> , 2022, 145, 1079-1097.	3.7	30
360	Comparison of [18 F]Flutemetamol and [11 C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. <i>NeuroImage: Clinical</i> , 2017, 16, 295-302.	1.4	30

#	ARTICLE	IF	CITATIONS
361	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2014, 35, 1483-1490.	1.5	29
362	A robust biomarker of large-scale network failure in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 152-161.	1.2	29
363	Decreased Glutamate Levels in Patients with Amnesic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB-PET Study. <i>Journal of Neuroimaging</i> , 2017, 27, 630-636.	1.0	29
364	Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 1-10.	1.2	29
365	Retinal signs and 20-year cognitive decline in the Atherosclerosis Risk in Communities Study. <i>Neurology</i> , 2018, 90, e1158-e1166.	1.5	29
366	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. <i>NeuroImage: Clinical</i> , 2019, 21, 101605.	1.4	29
367	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. <i>Neurology</i> , 2020, 94, e1793-e1802.	1.5	28
368	Detection of Alzheimer's disease amyloid beta 142, p-tau, and t-tau assays. <i>Alzheimer's and Dementia</i> , 2022, 18, 635-644.	0.4	28
369	Incidence of Dementia Among Participants and Nonparticipants in a Longitudinal Study of Cognitive Aging. <i>American Journal of Epidemiology</i> , 2014, 180, 414-423.	1.6	27
370	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1101-1104.	1.1	27
371	Multimorbidity and neuroimaging biomarkers among cognitively normal persons. <i>Neurology</i> , 2016, 86, 2077-2084.	1.5	27
372	Joint associations of β -amyloidosis and cortical thickness with cognition. <i>Neurobiology of Aging</i> , 2018, 65, 121-131.	1.5	27
373	Prevalence and Risk of Severe Cognitive Impairment in Advanced Chronic Kidney Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 393-399.	1.7	27
374	Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 91-105.	0.4	27
375	Association of Intracranial Atherosclerotic Disease With Brain β -Amyloid Deposition. <i>JAMA Neurology</i> , 2020, 77, 350.	4.5	27
376	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 49-59.	0.4	27
377	Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI. <i>Neurobiology of Aging</i> , 2020, 96, 176-183.	1.5	27
378	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. <i>Neurology</i> , 2020, 95, e23-e34.	1.5	27

#	ARTICLE	IF	CITATIONS
379	Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, 60-70.	0.4	27
380	Association of Initial β -Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 217.	4.5	27
381	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. <i>NeuroImage: Clinical</i> , 2021, 31, 102754.	1.4	27
382	The Metabolic Syndrome and Cognitive Decline in the Atherosclerosis Risk in Communities Study (ARIC). <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 337-346.	0.7	26
383	Contributions of imprecision in $\langle \text{PET} \rangle$ $\hat{=}$ $\langle \text{MRI} \rangle$ rigid registration to imprecision in amyloid $\langle \text{PET} \rangle$ $\langle \text{SUVR} \rangle$ measurements. <i>Human Brain Mapping</i> , 2017, 38, 3323-3336.	1.9	26
384	¹⁸ F- $\text{AV}1451$ uptake differs between dementia with lewy bodies and posterior cortical atrophy. <i>Movement Disorders</i> , 2019, 34, 344-352.	2.2	26
385	A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals. <i>Scientific Reports</i> , 2020, 10, 3869.	1.6	26
386	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. <i>Brain</i> , 2021, 144, 3212-3225.	3.7	26
387	Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD. <i>NeuroImage</i> , 2011, 54, 985-991.	2.1	25
388	Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1114-1120.	1.3	25
389	Population-Based Evaluation of Lumbar Puncture Opening Pressures. <i>Frontiers in Neurology</i> , 2019, 10, 899.	1.1	25
390	Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 261-274.	1.2	25
391	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 355.	1.7	25
392	Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 179-191.	0.6	25
393	Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks. <i>Neurology</i> , 2021, 97, 545-547.	1.5	25
394	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2015, 25, 269-274.	1.0	24
395	Tau-negative amnesic dementia masquerading as Alzheimer disease dementia. <i>Neurology</i> , 2018, 90, e940-e946.	1.5	24
396	Chronic Systemic Inflammation Is Associated With Symptoms of Late-Life Depression: The ARIC Study. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 87-98.	0.6	24

#	ARTICLE	IF	CITATIONS
397	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , 2021, 238, 118259.	2.1	24
398	Progressive familial leukodystrophy of late onset. <i>Neurology</i> , 1996, 46, 429-434.	1.5	23
399	Diabetes is Associated with Worse Executive Function in Both Eastern and Western Populations: Shanghai Aging Study and Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 167-176.	1.2	23
400	Role of β -Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2015, 72, 1475.	4.5	23
401	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. <i>Alzheimer's and Dementia</i> , 2016, 12, 510-515.	0.4	23
402	Timing of Physical Activity, Apolipoprotein E ϵ 4 Genotype, and Risk of Incident Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 2479-2486.	1.3	23
403	Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1345-1352.	1.2	23
404	Brain imaging measurements of fibrillar amyloid β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ϵ 4 allele. <i>Alzheimer's and Dementia</i> , 2020, 16, 598-609.	0.4	23
405	Revised Self-Monitoring Scale. <i>Neurology</i> , 2020, 94, e2384-e2395.	1.5	23
406	First PET Imaging Studies With ^{63}Zn -Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease. <i>Molecular Imaging</i> , 2016, 15, 153601211667379.	0.7	22
407	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. <i>Neurology</i> , 2016, 87, 691-698.	1.5	22
408	[ICA122]: THE MAYO CLINIC ADULT LIFE SPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFE SPAN. <i>Alzheimer's and Dementia</i> , 2017, 13, P93.	0.4	22
409	Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 281-290.	1.2	22
410	Rates of lobar atrophy in asymptomatic MAPT mutation carriers. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 338-346.	1.8	22
411	Association of Dietary Patterns in Midlife and Cognitive Function in Later Life in US Adults Without Dementia. <i>JAMA Network Open</i> , 2019, 2, e1916641.	2.8	22
412	Association of Longitudinal β -Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. <i>JAMA Network Open</i> , 2019, 2, e1916439.	2.8	22
413	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2016, 45, 107-108.	1.5	21
414	Olfactory function and neurocognitive outcomes in old age: The Atherosclerosis Risk in Communities Neurocognitive Study. <i>Alzheimer's and Dementia</i> , 2018, 14, 1015-1021.	0.4	21

#	ARTICLE	IF	CITATIONS
415	Brain volumetric deficits in <i>MAPT</i> mutation carriers: a multisite study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 95-110.	1.7	21
416	Observations on the short-term 'natural history' of probable Alzheimer's disease in a controlled clinical trial. <i>Neurology</i> , 1994, 44, 260-260.	1.5	21
417	Pharmacotherapy for Alzheimer's disease. <i>Current Neurology and Neuroscience Reports</i> , 2001, 1, 428-434.	2.0	20
418	Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. <i>Neurodegenerative Disease Management</i> , 2012, 2, 183-195.	1.2	20
419	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. <i>Neurobiology of Aging</i> , 2016, 46, 32-42.	1.5	20
420	The Association of Mid- and Late-Life Systemic Inflammation with Brain Amyloid Deposition: The ARIC-PET Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1041-1052.	1.2	20
421	TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnesic Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1227-1233.	1.2	20
422	Association Between Critical Care Admissions and Cognitive Trajectories in Older Adults*. <i>Critical Care Medicine</i> , 2019, 47, 1116-1124.	0.4	20
423	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2020, 16, 1013-1022.	0.4	20
424	Plasma amyloid β levels are driven by genetic variants near <i>APOE</i> , <i>BACE1</i> , <i>APP</i> , <i>PSEN2</i> : A genome-wide association study in over 12,000 non-demented participants. <i>Alzheimer's and Dementia</i> , 2021, 17, 1663-1674.	0.4	20
425	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. <i>Alzheimer's and Dementia</i> , 2022, 18, 602-611.	0.4	20
426	Genetic variants associated with risk of Alzheimer's disease contribute to cognitive change in midlife: The Atherosclerosis Risk in Communities Study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 269-282.	1.1	19
427	Recurrent perseverations on semantic verbal fluency tasks as an early marker of cognitive impairment. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018, 40, 832-840.	0.8	19
428	Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 210-216.	1.2	19
429	Recommendations for the nomenclature of cognitive change associated with anaesthesia and surgery—2018. <i>Acta Anaesthesiologica Scandinavica</i> , 2018, 62, 1473-1480.	0.7	19
430	Cerebrospinal fluid dynamics disorders. <i>Neurology</i> , 2019, 93, e2237-e2246.	1.5	19
431	Linear vs volume measures of ventricle size. <i>Neurology</i> , 2020, 94, e549-e556.	1.5	19
432	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With <i>MAPT</i> , <i>GRN</i> , and <i>C9orf72</i> Pathogenic Variants. <i>JAMA Network Open</i> , 2020, 3, e2022847.	2.8	19

#	ARTICLE	IF	CITATIONS
433	The temporal onset of the core features in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2022, 18, 591-601.	0.4	19
434	¹ H-MRS metabolites and rate of β^2 -amyloid accumulation on serial PET in clinically normal adults. <i>Neurology</i> , 2017, 89, 1391-1399.	1.5	18
435	Serum Vitamin D Concentrations and Cognitive Change Over 20 Years: The Atherosclerosis Risk in Communities Neurocognitive Study. <i>Neuroepidemiology</i> , 2018, 51, 131-137.	1.1	18
436	Automatic extraction and assessment of lifestyle exposures for Alzheimer's disease using natural language processing. <i>International Journal of Medical Informatics</i> , 2019, 130, 103943.	1.6	18
437	An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis. <i>Alzheimer's and Dementia</i> , 2020, 16, 1582-1590.	0.4	18
438	Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. <i>Neurology</i> , 2020, 94, e1571-e1579.	1.5	18
439	Association of Hospitalization with Long-Term Cognitive Trajectories in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 660-668.	1.3	18
440	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology. <i>Acta Neuropathologica Communications</i> , 2021, 9, 48.	2.4	18
441	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. <i>Alzheimer's and Dementia</i> , 2021, 17, 801-812.	0.4	18
442	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2021, 105, 252-261.	1.5	18
443	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic <i>MAPT</i> mutation carriers. <i>Neurology</i> , 2019, 93, e758-e765.	1.5	18
444	Detecting clinical change with the CDR τ -FTLD: differences between FTLD and AD dementia. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 977-982.	1.3	17
445	¹⁸ F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa040.	1.5	17
446	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 87, 556-567.	2.8	17
447	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 707-721.	1.7	17
448	Long-read targeted sequencing uncovers clinicopathological associations for <i>C9orf72</i> -linked diseases. <i>Brain</i> , 2021, 144, 1082-1088.	3.7	17
449	Pick's disease: clinicopathologic characterization of 21 cases. <i>Journal of Neurology</i> , 2020, 267, 2697-2704.	1.8	17
450	Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2023, 19, 4498-4506.	0.4	17

#	ARTICLE	IF	CITATIONS
451	Pharmacotherapy for Alzheimer's Disease: 2002. <i>Clinical Neuropharmacology</i> , 2003, 26, 93-101.	0.2	16
452	A computerized technique to assess language use patterns in patients with frontotemporal dementia. <i>Journal of Neurolinguistics</i> , 2010, 23, 127-144.	0.5	16
453	Utility of the Spanish version of the FTL D-modified CDR in the diagnosis and staging in frontotemporal lobar degeneration. <i>Journal of the Neurological Sciences</i> , 2014, 344, 63-68.	0.3	16
454	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. <i>Neurology: Genetics</i> , 2016, 2, e85.	0.9	16
455	Cortical Thickness and Anxiety Symptoms Among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2017, 29, 60-66.	0.9	16
456	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 877-883.	1.7	16
457	Neuroimaging findings in midlife and risk of late-life dementia over 20 years of follow-up. <i>Neurology</i> , 2019, 92, e917-e923.	1.5	16
458	Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1362-1369.	1.3	16
459	Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.5	16
460	Longitudinal Tracking of FTL D. <i>Alzheimer Disease and Associated Disorders</i> , 2007, 21, S58-S63.	0.6	15
461	β -Amyloidosis and neurodegeneration in Alzheimer disease. <i>Neurology</i> , 2014, 82, 1756-1757.	1.5	15
462	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. <i>Neurology</i> , 2017, 89, 2039-2048.	1.5	15
463	Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1273-1281.	1.2	15
464	Association Between Microinfarcts and Blood Pressure Trajectories. <i>JAMA Neurology</i> , 2018, 75, 212.	4.5	15
465	Relationships between β -amyloid and tau in an elderly population: An accelerated failure time model. <i>NeuroImage</i> , 2021, 242, 118440.	2.1	15
466	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. <i>Brain Communications</i> , 2022, 4, fcac013.	1.5	15
467	Alzheimer disease biomarkers and insights into mild cognitive impairment. <i>Neurology</i> , 2013, 80, 978-980.	1.5	14
468	Association of Hospitalization, Critical Illness, and Infection with Brain Structure in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1919-1926.	1.3	14

#	ARTICLE	IF	CITATIONS
469	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. <i>Neurobiology of Aging</i> , 2019, 83, 54-62.	1.5	14
470	Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa. <i>Alzheimer's and Dementia</i> , 2019, 15, 799-806.	0.4	14
471	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. <i>British Journal of Anaesthesia</i> , 2020, 124, 594-602.	1.5	14
472	CSF biomarkers in Olmsted County. <i>Neurology</i> , 2020, 95, e256-e267.	1.5	14
473	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. <i>Neurobiology of Aging</i> , 2020, 88, 42-50.	1.5	14
474	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1511-1523.	1.2	14
475	Associations Between Atrial Cardiopathy and Cerebral Amyloid: The ARIC-PET Study. <i>Journal of the American Heart Association</i> , 2020, 9, e018399.	1.6	14
476	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. <i>Acta Neuropathologica Communications</i> , 2022, 10, 16.	2.4	14
477	A longitudinal investigation of A β ² , anxiety, depression, and mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2022, 18, 1824-1831.	0.4	14
478	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. <i>Acta Neuropathologica</i> , 2022, 144, 159-160.	3.9	14
479	Dementia in MS complicated by coexistent Alzheimer disease. <i>Neurology: Clinical Practice</i> , 2014, 4, 226-230.	0.8	13
480	Informant-based hearing difficulties and the risk for mild cognitive impairment and dementia. <i>Age and Ageing</i> , 2019, 48, 888-894.	0.7	13
481	Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults. <i>British Journal of Anaesthesia</i> , 2019, 123, 808-817.	1.5	13
482	Cognitive function after surgery with regional or general anesthesia: A population-based study. <i>Alzheimer's and Dementia</i> , 2019, 15, 1243-1252.	0.4	13
483	Comparison of PC and iPad administrations of the Cogstate Brief Battery in the Mayo Clinic Study of Aging: Assessing cross-modality equivalence of computerized neuropsychological tests. <i>Clinical Neuropsychologist</i> , 2019, 33, 1102-1126.	1.5	13
484	Association between transactive response DNA-binding protein of 43 kDa type and cognitive resilience to Alzheimer's disease: a case-control study. <i>Neurobiology of Aging</i> , 2020, 92, 92-97.	1.5	13
485	β ² -Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. <i>Neurology</i> , 2021, 96, .	1.5	13
486	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. <i>Brain Communications</i> , 2021, 3, fcb076.	1.5	13

#	ARTICLE	IF	CITATIONS
487	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. <i>Journal of Neuroimaging</i> , 2021, 31, 1020-1027.	1.0	13
488	Association of Midlife Plasma Amyloid- β^2 Levels With Cognitive Impairment in Late Life. <i>Neurology</i> , 2021, 97, e1123-e1131.	1.5	13
489	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. <i>Neurology</i> , 2020, 95, e3190-e3202.	1.5	13
490	Language networks associated with computerized semantic indices. <i>NeuroImage</i> , 2015, 104, 125-137.	2.1	12
491	Abnormal expression of homeobox genes and transthyretin in <i>C9ORF72</i> expansion carriers. <i>Neurology: Genetics</i> , 2017, 3, e161.	0.9	12
492	Neural correlates of domain-specific cognitive decline. <i>Neurology</i> , 2019, 92, e1051-e1063.	1.5	12
493	Variants in <i>PPP2R2B</i> and <i>IGF2BP3</i> are associated with higher tau deposition. <i>Brain Communications</i> , 2020, 2, fcaa159.	1.5	12
494	Physical Activity and Trajectory of Cognitive Change in Older Persons: Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 377-388.	1.2	12
495	Prospective Analysis of Leisure-Time Physical Activity in Midlife and Beyond and Brain Damage on MRI in Older Adults. <i>Neurology</i> , 2021, 96, e964-e974.	1.5	12
496	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. <i>Brain Communications</i> , 2021, 3, fcab182.	1.5	12
497	Relationship Between Domain-Specific Cognitive Function and Speech-in-Noise Performance in Older Adults: The Atherosclerosis Risk in Communities Hearing Pilot Study. <i>American Journal of Audiology</i> , 2019, 28, 1006-1014.	0.5	12
498	The association of motoric cognitive risk with incident dementia and neuroimaging characteristics: The Atherosclerosis Risk in Communities Study. <i>Alzheimer's and Dementia</i> , 2022, 18, 434-444.	0.4	12
499	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. <i>Brain Communications</i> , 2022, 4, fcac017.	1.5	12
500	Alzheimer's disease and related dementias and heart failure: A community study. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 1664-1672.	1.3	12
501	Incident Heart Failure and Cognitive Decline: The Atherosclerosis Risk in Communities Study. <i>Journal of Cardiac Failure</i> , 2017, 23, 47-55.	0.7	11
502	Patients come from populations and populations contain patients. A two-stage scientific and ethics review: The next adaptation for single institutional review boards. , 2017, 13, 940-946.		11
503	Incidence of frontotemporal disorders in Olmsted County: A population-based study. <i>Alzheimer's and Dementia</i> , 2020, 16, 482-490.	0.4	11
504	Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, 1115-1124.	0.4	11

#	ARTICLE	IF	CITATIONS
505	Plasma phospholipid very-long-chain SFAs in midlife and 20-year cognitive change in the Atherosclerosis Risk in Communities (ARIC): a cohort study. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 1252-1258.	2.2	11
506	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 99, 11-18.	1.5	11
507	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. <i>Brain Communications</i> , 2021, 3, fcaa238.	1.5	11
508	The Relationship of APOE ϵ 4, Race, and Sex on the Age of Onset and Risk of Dementia. <i>Frontiers in Neurology</i> , 2021, 12, 735036.	1.1	11
509	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2022, 37, 1256-1264.	2.2	11
510	Neuropathologic scales of cerebrovascular disease associated with diffusion changes on MRI. <i>Acta Neuropathologica</i> , 2022, 144, 1117-1125.	3.9	11
511	Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 2274-2281.	1.3	10
512	The influence of β -amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. <i>Neurology</i> , 2019, 92, e710-e722.	1.5	10
513	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid- β PET Signal. <i>Neurology</i> , 2021, 97, e1799-e1808.	1.5	10
514	Talking points for physicians, patients and caregivers considering Aduhelm [®] infusion and the accelerated pathway for its approval by the FDA. <i>Molecular Neurodegeneration</i> , 2021, 16, 74.	4.4	10
515	Associations of Vascular Risk and Amyloid Burden with Subsequent Dementia. <i>Annals of Neurology</i> , 2022, 92, 607-619.	2.8	10
516	Tacrine for Alzheimer's Disease. <i>Pharmacoeconomics</i> , 1995, 7, 275-279.	1.7	9
517	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. <i>Journal of Neuro-Oncology</i> , 2018, 136, 373-378.	1.4	9
518	Association of non-exercise physical activity in mid- and late-life with cognitive trajectories and the impact of APOE ϵ 4 genotype status: the Mayo Clinic Study of Aging. <i>European Journal of Ageing</i> , 2019, 16, 491-502.	1.2	9
519	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenocopy in Mapt Mutation Carriers. <i>Journal of Neuroimaging</i> , 2019, 29, 624-629.	1.0	9
520	Cognitive Reserve in Midlife is not Associated with Amyloid- β Deposition in Late-Life. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 517-521.	1.2	9
521	The Enigma of Decreasing Dementia Incidence. <i>JAMA Network Open</i> , 2020, 3, e2011199.	2.8	9
522	Association of Cortical and Subcortical β -Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021, 33, 64-71.	0.9	9

#	ARTICLE	IF	CITATIONS
523	Cerebral Microbleeds. <i>Stroke</i> , 2021, 52, 2347-2355.	1.0	9
524	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2022, 112, 16-26.	1.5	9
525	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging. <i>NeuroImage</i> , 2022, 251, 119020.	2.1	9
526	Donepezil 23 mg. <i>Neurology: Clinical Practice</i> , 2012, 2, 352-355.	0.8	8
527	Diagnostic tests for Alzheimer disease. <i>Neurology: Clinical Practice</i> , 2012, 2, 151-153.	0.8	8
528	The Telephone Interview for Cognitive Status. <i>Cognitive and Behavioral Neurology</i> , 2018, 31, 158-158.	0.5	8
529	Associations Between Left Ventricular Structure, Function, and Cerebral Amyloid. <i>Stroke</i> , 2019, 50, 3622-3624.	1.0	8
530	Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volume—Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2431-2436.	1.1	8
531	Functional Activity and Neuropsychiatric Symptoms in Normal Aging and Mild Cognitive Impairment. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 68-71.	0.6	8
532	Association of Hypertension According to New American College of Cardiology/American Heart Association Blood Pressure Guidelines With Incident Dementia in the ARIC Study Cohort. <i>Journal of the American Heart Association</i> , 2020, 9, e017546.	1.6	8
533	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 113-122.	1.2	8
534	Sex Difference in the Relation Between Marital Status and Dementia Risk in Two Population-Based Cohorts. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1269-1279.	1.2	8
535	Causal structure discovery identifies risk factors and early brain markers related to evolution of white matter hyperintensities. <i>NeuroImage: Clinical</i> , 2022, 35, 103077.	1.4	8
536	Long-term tacrine treatment effects. <i>Neurology</i> , 1998, 50, 567-568.	1.5	7
537	Preclinical Alzheimer disease — the new frontier. <i>Nature Reviews Neurology</i> , 2016, 12, 620-621.	4.9	7
538	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 736-743.	1.2	7
539	Prognosis of Patients with Behavioral Variant Frontotemporal Dementia Who have Focal Versus		

#	ARTICLE	IF	CITATIONS
541	Highly Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 2353-2361.	1.3	7
542	Plasma Metabolites Associated with Brain MRI Measures of Neurodegeneration in Older Adults in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). <i>International Journal of Molecular Sciences</i> , 2019, 20, 1744.	1.8	7
543	Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2019, 79, 43-49.	1.5	7
544	Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2785-2793.	1.1	7
545	Brain MRI after critical care admission: A longitudinal imaging study. <i>Journal of Critical Care</i> , 2021, 62, 117-123.	1.0	7
546	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 683-693.	1.2	7
547	Brain White Matter Structure and Amyloid Deposition in Black and White Older Adults: The ARIC PET Study. <i>Journal of the American Heart Association</i> , 2021, 10, e022087.	1.6	7
548	A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimer's Disease Based on Cogstate One Card Learning Accuracy Performance. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 861-877.	1.2	7
549	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. <i>Neurobiology of Aging</i> , 2021, 110, 27-36.	1.5	7
550	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases. <i>Journal of Neurology</i> , 2022, 269, 4110-4128.	1.8	7
551	Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying. , 2006, 2, 147-149.		6
552	Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease. , 2007, 3, 21-22.		6
553	Effects of age and dementia on temporal cycles in spontaneous speech fluency. <i>Journal of Neurolinguistics</i> , 2011, 24, 619-635.	0.5	6
554	Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE ϵ 4 Allele. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 172.	1.7	6
555	Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a population-based sample. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 127-130.	1.2	6
556	Cerebrovascular disease affects brain structural integrity long before clinically overt strokes. <i>Neurology</i> , 2017, 89, 110-111.	1.5	6
557	Sifting through a failed Alzheimer trial. <i>Neurology</i> , 2018, 90, 447-448.	1.5	6
558	Endurance and gait speed relationships with mild cognitive impairment and dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12281.	1.2	6

#	ARTICLE	IF	CITATIONS
559	Poly (ADP-Ribose) and α -synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity. PLoS ONE, 2022, 17, e0264446.	1.1	6
560	Association of Carotid Intima-Media Thickness with Brain MRI Markers in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106388.	0.7	6
561	Artificial Intelligence-Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. Mayo Clinic Proceedings, 2022, 97, 871-880.	1.4	6
562	Dementia: Many roads, but not built in a day. Neurology, 2007, 69, 2193-2194.	1.5	5
563	Frequency of Acute and Subacute Infarcts in a Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 300-306.	1.4	5
564	Longitudinal flortaucipir ([¹⁸ F]AV-1451) PET imaging in primary progressive apraxia of speech. Cortex, 2020, 124, 33-43.	1.1	5
565	Association of mid-life serum lipid levels with late-life brain volumes: The atherosclerosis risk in communities neurocognitive study (ARIC NCS). NeuroImage, 2020, 223, 117324.	2.1	5
566	Lack of physical activity, neuropsychiatric symptoms and the risk of incident mild cognitive impairment in older community-dwelling individuals. German Journal of Exercise and Sport Research, 2021, 51, 487-494.	1.0	5
567	Alzheimer Disease Spectrum. Neurology, 2021, 96, 299-300.	1.5	5
568	Amyloid- and tau-PET imaging in a familial prion kindred. Neurology: Genetics, 2018, 4, e290.	0.9	4
569	Non-right handed primary progressive apraxia of speech. Journal of the Neurological Sciences, 2018, 390, 246-254.	0.3	4
570	Mid- and Late-Life Leisure-Time Physical Activity and Global Brain Amyloid Burden: The Atherosclerosis Risk in Communities (ARIC)-PET Study. Journal of Alzheimer's Disease, 2020, 76, 139-147.	1.2	4
571	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	1.8	4
572	Distinguishing Frontotemporal Dementia From Alzheimer Disease Through Everyday Function Profiles: Trajectories of Change. Journal of Geriatric Psychiatry and Neurology, 2021, 34, 66-75.	1.2	4
573	Relation of Diabetes Mellitus to Incident Dementia in Patients With Atrial Fibrillation (from the Tj ETQq1 1 0.784314 rgBT /O verlock 10	0.7	4
574	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547.	1.2	4
575	Kidney-Metabolic Factors Associated with Cognitive Impairment in Chronic Kidney Disease: A Pilot Study. American Journal of Nephrology, 2022, 53, 435-445.	1.4	4
576	Physical Frailty and Brain White Matter Abnormalities: The ARIC Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 0, , .	1.7	4

#	ARTICLE	IF	CITATIONS
577	Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt-Jakob disease and autoimmune encephalitis. <i>European Journal of Neurology</i> , 2022, 29, 2905-2912.	1.7	4
578	Healthy young hearts sharper older minds make. <i>Annals of Neurology</i> , 2013, 73, 151-152.	2.8	3
579	ICP&P&127: VARIABILITY IN MRI AND PET MEASUREMENTS INTRODUCED BY CHANGE IN MRI VENDOR. <i>Alzheimer's and Dementia</i> , 2019, 15, P104.	0.4	3
580	Association Between Neuropsychiatric Symptoms and Functional Change in Older Non-Demented Adults: Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 911-917.	1.2	3
581	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. <i>Neurobiology of Aging</i> , 2020, 92, 135-140.	1.5	3
582	Brain amyloid, cortical thickness, and changes in activities of daily living. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 474-485.	1.7	3
583	CSF dynamics as a predictor of cognitive progression. <i>NeuroImage</i> , 2021, 232, 117899.	2.1	3
584	Chronic Kidney Disease Associated with Worsening White Matter Disease and Ventricular Enlargement. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1729-1740.	1.2	3
585	Young-Onset Dementia"New Insights for an Underappreciated Problem. <i>JAMA Neurology</i> , 2021, 78, 1055.	4.5	3
586	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. <i>NeuroImage: Clinical</i> , 2022, 34, 102954.	1.4	3
587	Association of Performance on the Financial Capacity Instrument"Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults. <i>Neurology: Clinical Practice</i> , 2022, 12, 113-124.	0.8	3
588	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer"s disease. <i>Acta Neuropathologica</i> , 2022, 143, 571-583.	3.9	3
589	Alzheimer's Disease and Other Dementias. , 2012, , 2274-2283.		2
590	Is dominantly inherited Alzheimer disease a clone of sporadic Alzheimer disease?. <i>Neurology</i> , 2015, 85, 750-751.	1.5	2
591	Beyond clinical syndromes in primary progressive aphasia. <i>Neurology</i> , 2017, 88, 2244-2245.	1.5	2
592	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. <i>Neurology: Genetics</i> , 2017, 3, e201.	0.9	2
593	Extending Alzheimer disease biomarker studies into the Hispanic community. <i>Neurology</i> , 2020, 95, 665-666.	1.5	2
594	Preoperative cognitive impairment associated with oversedation during recovery from anesthesia. <i>Journal of Anesthesia</i> , 2020, 34, 390-396.	0.7	2

#	ARTICLE	IF	CITATIONS
595	The quest for dementia prevention does not include an aspirin a day. <i>Neurology</i> , 2020, 95, 105-106.	1.5	2
596	Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report. <i>Journal of prevention of Alzheimer's disease</i> , The, 2022, 9, 231-235.	1.5	2
597	Polygenic Scores of Alzheimer's Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1615-1625.	1.2	2
598	Commentary: "Treatment of hypertension and prevention of dementia" by Oliver Hanon and Françoise Forette. , 2005, 1, 41-42.		1
599	MRS in Early and Presymptomatic Carriers of a Novel Octapeptide Repeat Insertion in the Prion Protein Gene. <i>Journal of Neuroimaging</i> , 2013, 23, 409-413.	1.0	1
600	P2-079: ALZHEIMER'S AND VASCULAR DISEASE-SPECIFIC STRUCTURAL BRAIN CHANGES IN CHRONIC KIDNEY DISEASE PATIENTS. , 2014, 10, P498-P499.		1
601	Letter to the Editor re: Nexus of Cancer & Alzheimer's. <i>Alzheimer's and Dementia</i> , 2017, 13, 722-722.	0.4	1
602	P2-334: THE INFLUENCE OF BETA-AMYLOID ON THE PROGRESSION OF PROGRESSIVE APRAXIA OF SPEECH. <i>Alzheimer's and Dementia</i> , 2018, 14, P810.	0.4	1
603	Incidence of Convex Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 104451.	0.7	1
604	Gait Speed and Instrumental Activities of Daily Living in Older Adults After Hospitalization: A Longitudinal Population-Based Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, e272-e280.	1.7	1
605	Cognitive Heterogeneity in Alzheimer Clinical Trials. <i>Neurology</i> , 2021, 96, 1017-1018.	1.5	1
606	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. , 2011, 7, 263.		1
607	Associations between cerebrospinal fluid total phosphatidylcholines, neurodegeneration, cognitive decline, and risk of mild cognitive impairment in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2020, 93, 52-54.	1.5	1
608	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-6.	1.2	1
609	White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12269.	1.2	1
610	Acute Strychnine-Induced Seizures in Cats:A Golgi Study. <i>Epilepsia</i> , 1975, 16, 791-792.	2.6	0
611	Tacrine Treatment and Nursing Home Placement: Application of the Cox Proportional Hazards Model With Time-Dependent Covariates. <i>Drug Information Journal</i> , 1998, 32, 729-735.	0.5	0
612	Continuing the Tradition of Neuroanatomic Excellence. <i>Journal of the International Neuropsychological Society</i> , 2005, 11, 117-118.	1.2	0

#	ARTICLE	IF	CITATIONS
613	Response to Letter from Dr. William Hazzard. Journal of the American Geriatrics Society, 2009, 57, 1317-1317.	1.3	0
614	F1-02-01: Mayo Clinic Study of Aging. , 2010, 6, S62-S62.		0
615	F4-03-03: Interpretation of delayed start trial data: Implications for researchers, clinicians, and patients. , 2015, 11, P262-P263.		0
616	Two Authors Reply. American Journal of Epidemiology, 2015, 181, 292-293.	1.6	0
617	FTS3â€”01â€”02: Epidemiology of Vascular Related Risk Factors for Dementia. Alzheimer's and Dementia, 2016, 12, P276.	0.4	0
618	O2â€”08â€”01: Av1451 Pet Imaging in the Spectrum of Alzheimer's Disease from Clinically Normal to Dementia. Alzheimer's and Dementia, 2016, 12, P243.	0.4	0
619	Behavioral Variant Frontotemporal Dementia. JAMA Neurology, 2016, 73, 1051.	4.5	0
620	[P4â€”015]: INTERNATIONAL SCIENTIFIC, ETHICAL AND REGULATORY REVIEW FOR ALZHEIMER'S CLINICAL TRIALS. Alzheimer's and Dementia, 2017, 13, P1259.	0.4	0
621	[O1â€”09â€”02]: RELATIONSHIPS OF VERY SMALL, INFARCT-LIKE LESIONS WITH 20-YEAR COGNITIVE DECLINE: THE ARIC STUDY. Alzheimer's and Dementia, 2017, 13, P211.	0.4	0
622	[O1â€”12â€”05]: CONTINUOUS MEASURES OF Î²â€”AMYLOIDOSIS AND CORTICAL THICKNESS IN RELATION TO COGNITIVE DECLINE IN COGNITIVELY NORMAL INDIVIDUALS: A POPULATION-BASED STUDY. Alzheimer's and Dementia, 2017, 13, P223.	0.4	0
623	[O2â€”12â€”04]: EFFECTS OF CEREBROVASCULAR INFARCT BURDEN ON COGNITIVE DECLINE IN THE PRESENCE OF DEMENTIA AND DEATH: ACCOUNTING FOR POTENTIALLY INFORMATIVE DROPOUT USING COMPETING RISK SHARED PARAMETER MODELS: THE ARIC STUDY. Alzheimer's and Dementia, 2017, 13, P586.	0.4	0
624	Microinfarcts and blood pressure trajectories: response to Dr Niu et al.. Journal of Human Hypertension, 2018, 32, 385-385.	1.0	0
625	O1â€”03â€”05: ENTORHINAL CORTEX TAU PET, CORTICAL THICKNESS AND MEMORY PERFORMANCE IN COGNITIVELY UNIMPAIRED PERSONS. Alzheimer's and Dementia, 2018, 14, P221.	0.4	0
626	Early-Phase Randomized Clinical Trialsâ€”Expectations vs Hard Reality. JAMA Neurology, 2019, 76, 15.	4.5	0
627	Scientific Advising and Reviewing: On strengthening the bond between the Alzheimer's Association and the scientific community. Alzheimer's and Dementia, 2020, 16, 1095-1098.	0.4	0
628	Medical Doctors and Dementia: A Longitudinal Study. Journal of the American Geriatrics Society, 2020, 68, 1250-1255.	1.3	0
629	The Principle Syndromes of Dementia. , 2004, , 1216-1233.		0
630	Abstract P237: Measuring Cognition in the Atherosclerosis Risk in Communities (ARIC) Study Cohort: An approach to Account for Informative Attrition. Circulation, 2015, 131, .	1.6	0

#	ARTICLE	IF	CITATIONS
631	Association of Indication for Hospitalization With Subsequent Amyloid Positron Emission Tomography and Magnetic Resonance Imaging Biomarkers. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2023, 78, 304-313.	1.7	0
632	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. <i>Neurology</i> , 2022, , 10.1212/WNL.0000000000200582.	1.5	0
633	CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease. <i>Nature Reviews Neurology</i> , 0, , .	4.9	0
634	Hypertension and Racial Differences in Dementia Reveal a Strategy for Risk Reduction in All Races. <i>American Journal of Hypertension</i> , 0, , .	1.0	0